Conjugation strategy shapes antitumor efficacy and enables dose-sparing in non-antibody protein nanoconjugates.

ABSTRACT: Precision targeting is a hot topic in cancer nanomedicine, as conventional chemotherapies cause systemic toxicities, creating an urgent need for more selective treatments. Although antibody-drug conjugates (ADCs) are the current gold standard in targeted therapy, their clinical performance remains limited. As an alternative, we previously developed a multivalent protein nanocarrier (T22-GFP-H6) displaying the CXCR4-targeting peptide T22, which offers super-selective tumor accumulation driven by CXCR4 overexpression. This innovative nanovehicle showed favorable biodistribution for targeted delivery of antitumor drugs, including monomethyl auristatin E (MMAE), in a first-generation stochastic nanoconjugate format. However, unlike ADCs, where conjugation strategy is known to influence pharmac

SUBMITTER: Rueda A 

PROVIDER: S-EPMC12813365 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature